GlassScriptPhysician profile
Lindsay Castro
NPI 1508695016
$2,414.22
in general payments reported to CMS, 2019-2025
34 companies · $2,397 in 2025
The $2,397 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $16.92 · 2025: $2,397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,414.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,414.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $181.55 | 2025 | Libtayo |
| Astrazeneca Pharmaceuticals LP | $181.06 | 2025 | Imfinzi, Calquence, Enhertu |
| Daiichi Sankyo INC. | $166.50 | 2025 | Datroway, Enhertu |
| Boston Scientific Corporation | $143.83 | 2025 | Intracept Rf Probe |
| Merck Sharp & Dohme LLC | $141.46 | 2025 | Keytruda, Keytruda Qlex, Lynparza |
| Baxter Healthcare | $136.76 | 2025 | Seprafilm, Tisseel, Floseal |
| Si-Bone, INC. | $133.16 | 2025 | |
| Tersera Therapeutics LLC | $101.95 | 2025 | Zoladex |
| Novartis Pharmaceuticals Corporation | $98.41 | 2025 | |
| Eisai INC. | $88.31 | 2025 | |
| Incyte Corporation | $86.39 | 2025 | Monjuvi, Zynyz, Jakafi |
| Glaxosmithkline, LLC. | $85.28 | 2025 | Jemperli, Zejula, Ojjaara |
| Genentech USA, INC. | $79.49 | 2025 | Tecentriq, Polivy |
| Bayer Healthcare Pharmaceuticals INC. | $76.98 | 2025 | |
| Janssen Biotech, INC. | $66.79 | 2025 | Erleada, Darzalex, Tecvayli |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iovance Biotherapeutics, INC. | $63.65 | 2025 | Amtagvi |
| Legend Biotech USA INC. | $60.17 | 2025 | Carvykti |
| Abbvie INC. | $55.59 | 2025 | |
| Emd Serono, INC. | $55.50 | 2025 | |
| Pharmaessentia USA Corporation | $45.76 | 2025 | Besremi |
| Takeda Pharmaceuticals U.S.A., INC. | $43.99 | 2025 | Fruzaqla |
| Genzyme Corporation | $42.14 | 2025 | |
| Pharmacosmos Therapeutics INC. | $35.25 | 2025 | Monoferric |
| Springworks Therapeutics, INC. | $28.06 | 2025 | Ogsiveo |
| Agios Pharmaceuticals, INC. | $27.80 | 2025 | Pyrukynd |
| Kite Pharma, INC. | $24.57 | 2025 | Yescarta |
| Geron Corporation | $23.69 | 2025 | Rytelo |
| Ipsen Biopharmaceuticals, INC | $22.30 | 2025 | Somatuline Depot, Onivyde |
| Corcept Therapeutics | $22.25 | 2025 | Korlym |
| Merz Pharmaceuticals, LLC | $22.00 | 2025 | Xeomin |
| Puma Biotechnology, INC. | $21.04 | 2025 | |
| Servier Pharmaceuticals LLC | $19.78 | 2025 | |
| Ironshore Pharmaceuticals INC. | $16.92 | 2024 | |
| Aveo Pharmaceuticals, INC. | $15.84 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsay Castro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.